For the Inventor, By the Inventor

Enter assignee name

Bothell, WA, United States of America

Nastech Pharmaceutical Company, Inc.

USPTO Granted Patents = 21

% Expired Patents = 38.1

Trademarks = 1

Forward Citations = 322

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Steven C Quay (9 out of 94 patents)

Charanjit R Behl (8 out of 10 patents)

Anthony P Sileno (8 out of 18 patents)

4. Vincent D Romeo (8 out of 8 patents)

5. Jorge C deMeireles (5 out of 5 patents)

6. Mary S Kleppe (4 out of 5 patents)

7. Gordon Brandt (4 out of 4 patents)

8. Jeffrey Wenig (4 out of 5 patents)

9. Conor J MacEvilly (3 out of 3 patents)

10. Raja G Achari (3 out of 5 patents)

11. Shamim Ahmed (2 out of 2 patents)

12. Tianquing Liu (2 out of 2 patents)

13. Harish K Pimplaskar (2 out of 2 patents)

14. Wei J Xia (2 out of 2 patents)

15. Henry R Costantino (1 out of 91 patents)

21 patents: Sort by Forward Citations

1. 7863245 - Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity (2011-01-04),

2. 7329725 - Phage displayed Trp cage ligands (2008-02-12),

3. 7244709 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone (2007-07-17),

4. 7229966 - Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-06-12),

5. 7229636 - Cyanocobalamin low viscosity aqueous formulations for intranasal delivery (2007-06-12),

6. 7186692 - Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-03-06),

7. 7186691 - Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-03-06),

8. 7166575 - Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity (2007-01-23),

9. 7157426 - Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-01-02),

10. 6740660 - Nasal delivery of apomorphine (2004-05-25),

11. 6677346 - Methods comprising intranasal morphine (2004-01-13),

12. 6599883 - Nasal delivery of xylitol (2003-07-29),

13. 6451848 - Compositions and methods comprising morphine gluconate (2002-09-17),

14. 6436950 - Nasal delivery of apomorphine (2002-08-20),

15. 6225343 - Compositions and methods comprising morphine gluconate (2001-05-01),

Company Overview

Nastech Pharmaceutical Company, Inc. is a biotechnology firm based in Bothell, Washington, focused on developing innovative drug delivery systems and therapeutic solutions. The company specializes in the formulation of nasal and oral drug delivery technologies, aiming to enhance the efficacy and patient compliance of various medications. Nastech's research efforts are directed towards addressing unmet medical needs across multiple therapeutic areas, leveraging advanced science to improve health outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

21 Patents

#25 in Bothell, WA

#336 in Washington

#15,712 in US

#30,001 in the World

Bothell, WA, United States of America

Nastech Pharmaceutical Company, Inc.

Forward Citations = 322

24 inventors:

Steven C Quay (9 out of 94 patents)

Charanjit R Behl (8 out of 10 patents)

Anthony P Sileno (8 out of 18 patents)

4. Vincent D Romeo (8 out of 8 patents)

5. Jorge C deMeireles (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nastech Pharmaceutical Company, Inc.. Retrieved from https://idiyas.com/company/nastech-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…